University of Aberdeen logo

AURA - Aberdeen University Research Archive

 

Durvalumab (MEDI 4736) in combination with extended neoadjuvant regimens in rectal cancer : a study protocol of a randomised phase II trial (PRIME-RT)

Simple item page
dc.contributor.authorHanna, Catherine R.
dc.contributor.authorO’Cathail, Sean M.
dc.contributor.authorGraham, Janet S.
dc.contributor.authorSaunders, Mark
dc.contributor.authorSamuel, Leslie
dc.contributor.authorHarrison, Mark
dc.contributor.authorDevlin, Lynsey
dc.contributor.authorEdwards, Joanne
dc.contributor.authorGaya, Daniel R.
dc.contributor.authorKelly, Caroline A.
dc.contributor.authorLewsley, Liz-Anne
dc.contributor.authorMaka, Noori
dc.contributor.authorMorrison, Paula
dc.contributor.authorDinnett, Louise
dc.contributor.authorDillon, Susan
dc.contributor.authorGourlay, Jacqueline
dc.contributor.authorPlatt, Jonathan J.
dc.contributor.authorThomson, Fiona
dc.contributor.authorAdams, Richard A.
dc.contributor.authorRoxburgh, Campbell S. D.
dc.contributor.institutionUniversity of Aberdeen.Medicine, Medical Sciences & Nutritionen
dc.contributor.institutionUniversity of Aberdeen.Aberdeen Centre for Evaluationen
dc.contributor.institutionUniversity of Aberdeen.Medical Educationen
dc.date.accessioned2021-09-16T08:49:01Z
dc.date.available2021-09-16T08:49:01Z
dc.date.issued2021-08-26
dc.descriptionAcknowledgements We are grateful to Mr George Davidson and Ms Monica Jeffers for their input with writing the PRIME-RT protocol and patient information sheet. This study is co-sponsored by the University of Glasgow and NHS Greater Glasgow and Clyde. Funding PRIME-RT is funded by Astrazeneca and receives core funding from CRUK Clinical Trials Unit Glasgow for the purposes of trial set-up and data collection. The trial is co-sponsored by the University Of Glasgow and NHS Greater Glasgow and Clyde.en
dc.description.statusPeer revieweden
dc.format.extent9
dc.format.extent936077
dc.identifier200469973
dc.identifierb69570ed-8a88-4383-aae4-f6d3dea53b2d
dc.identifier85113425297
dc.identifier.citationHanna, C R, O’Cathail, S M, Graham, J S, Saunders, M, Samuel, L, Harrison, M, Devlin, L, Edwards, J, Gaya, D R, Kelly, C A, Lewsley, L-A, Maka, N, Morrison, P, Dinnett, L, Dillon, S, Gourlay, J, Platt, J J, Thomson, F, Adams, R A & Roxburgh, C S D 2021, 'Durvalumab (MEDI 4736) in combination with extended neoadjuvant regimens in rectal cancer : a study protocol of a randomised phase II trial (PRIME-RT)', Radiation Oncology, vol. 16, no. 1, 163. https://doi.org/10.1186/s13014-021-01888-1en
dc.identifier.doi10.1186/s13014-021-01888-1
dc.identifier.iss1en
dc.identifier.issn1748-717X
dc.identifier.otherRIS: urn:E6659C9791D353F3A3CEE3CD3A4F63D6
dc.identifier.otherRIS: Hanna2021
dc.identifier.otherORCID: /0000-0002-8402-8670/work/100345921
dc.identifier.urihttps://hdl.handle.net/2164/17086
dc.identifier.vol16en
dc.language.isoeng
dc.relation.ispartofRadiation Oncologyen
dc.subjectSDG 3 - Good Health and Well-beingen
dc.subjectRectalen
dc.subjectneoplasmen
dc.subjectchemotherapyen
dc.subjectradiotherapyen
dc.subjectimmune-oncologyen
dc.subjectimmunotherapyen
dc.subjectclinical trialen
dc.subjectR Medicineen
dc.subjectCancer Research UKen
dc.subjectSupplementary Informationen
dc.subject.lccRen
dc.titleDurvalumab (MEDI 4736) in combination with extended neoadjuvant regimens in rectal cancer : a study protocol of a randomised phase II trial (PRIME-RT)en
dc.typeJournal articleen

Files

Original bundle

Now showing 1 - 1 of 1
Thumbnail Image
Name:
Hanna_etal_RO_Durvalumb_MEDI4736_in_VOR.pdf
Size:
914.14 KB
Format:
Adobe Portable Document Format
Download

Collections

All research